6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Journal of Steroid Biochemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0022-4731(88)90129-XPMID 3386266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.

  1986cited by this paper
• 1-Methyl-1,4-androstadiene-3,17-dione (SH 489): characterization of an irreversible inhibitor of estrogen biosynthesis.

  1986cited by this paper
• Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.

  1986cited by this paper
• Biochemical and endocrine properties of a mechanism-based inhibitor of aromatase.

  1984cited by this paper
• Binding of a 4-methyl-4-aza-steroid to 5 alpha-reductase of rat liver and prostate microsomes.

  1983cited by this paper
• Prostatic cancer--II. Inhibitors of rat prostatic 4-ene-3-ketosteroid 5 alpha-reductase derived from 6-methylene-4-androsten-3-ones.

  1983cited by this paper
• A new hypothesis based on suicide substrate inhibitor studies for the mechanism of action of aromatase.

  1982cited by this paper
• Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity.

  1981cited by this paper
• Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo.

  1981cited by this paper
• Screening for anti-hormones by receptor studies.

  1975cited by this paper
• Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione.

  1974cited by this paper
• Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase.

  1962cited by this paper
• Biological aromatization of steroids.

  1959cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Functionalized nitrogen- and chalcogen-containing heterocyclic compounds as aromatase inhibitors: Design, synthesis and biological evaluation.

  2025cites this paper
• Cytochrome P450 in GtoPdb v.2025.3

  2025cites this paper
• Strategies to inhibit steroid cytochrome P450 enzymes to benefit human health: development of steroid ligands for P450s 17A1, 19A1, and 8B1 to treat cancer and obesity.

  2025cites this paper
• Recent Studies on Aromatase and EGFR Involved in Breast Cancer and their Inhibitors

  2024cites this paper
• Aromatase inhibitors for the treatment of breast cancer: An overview (2019-2023).

  2024cites this paper
• Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates

  2022cites this paper
• HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

  2022cites this paper
• Cytochrome P450 in GtoPdb v.2021.2

  2021cites this paper
• Anti-masculinization induced by aromatase inhibitors in adult female zebrafish

  2020cites this paper
• Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.

  2020cites this paper
• Recent Studies on Aromatase and Sulfatase Involved in Breast Cancer and their Inhibitors

  2020cites this paper
• Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives

  2020cites this paper
• Small molecule inhibitors and stimulators of inducible nitric oxide synthase in cancer cells from natural origin (phytochemicals, marine compounds, antibiotics).

  2020cites this paper
• Safety Pharmacology

  2019cites this paper
• The beneficial androgenic action of steroidal aromatase inactivators in estrogen-dependent breast cancer after failure of nonsteroidal drugs

  2019cites this paper
• Identification of new probe substrates for human CYP20A1

  2019cites this paper
• Extraction and determination of trace amounts of three anticancer pharmaceuticals in urine by three-phase hollow fiber liquid-phase microextraction based on two immiscible organic solvents followed by high-performance liquid chromatography.

  2018cites this paper
• Gender-Related Differences in Lung Cancer

  2018cites this paper
• Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1

  2018cites this paper
• Quinone‐related hexacyclic by‐products in the production process of exemestane

  2017cites this paper
• Potential repositioning of exemestane as a neuroprotective agent for Parkinson’s disease

  2017cites this paper
• Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.

  2016cites this paper
• Theoretical Study of the Mechanism of Exemestane Hydroxylation Catalyzed by Human Aromatase Enzyme.

  2016cites this paper
• Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

  2016cites this paper
• Unravelling exemestane: From biology to clinical prospects.

  2016cites this paper
• Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases

  2016cites this paper
• Transcriptional control of local estrogen formation by aromatase in the breast.

  2015cites this paper
• New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

  2014cites this paper
• Phenotypic screening in cancer drug discovery — past, present and future

  2014cites this paper
• Aromatase inhibitors produce hypersensitivity in experimental models of pain : studies in vivo and in isolated sensory neurons

  2014influential citation
• Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.

  2014cites this paper
• Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention

  2013cites this paper
• Anticancer steroids: linking natural and semi-synthetic compounds.

  2013cites this paper
• COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT

  2013cites this paper
• Refined preparation of 1alpha,3-dipyrrolidino-androsta-3,5-diene-17-one, a key intermediate in the exemestane synthesis.

  2012cites this paper
• Exemestane

  2012cites this paper
• La 7β-hydroxy-épiandrostérone dans des modèles in vitro de cancer du sein : effets anti-estrogéniques et rôle des récepteurs des estrogènes

  2012cites this paper
• Exemestane for breast cancer prevention: a critical shift?

  2012cites this paper
• Chapter 10 – Safety Pharmacology

  2012cites this paper
• Novel aromatase inhibitors by structure-guided design.

  2012cites this paper
• Practical synthesis of precursor of [N-methyl-11C]vorozole, an efficient PET tracer targeting aromatase in the brain.

  2011cites this paper
• Impaired reproduction in adult male, but not female, rats following juvenile treatment with the aromatase inhibitor, exemestane.

  2011cites this paper
• Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometry.

  2011cites this paper
• Substituted androstanes as aromatase inhibitors

  2010cites this paper
• Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.

  2010cites this paper
• Development of Estrogen Antagonists as Pharmaceutical Agents

  2010cites this paper
• Combined chemical and microbiological synthesis of exemes- tane from sitosterol

  2010cites this paper
• Combined chemical and microbiological synthesis of exemestane from sitosterol

  2010cites this paper
• Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients

  2010cites this paper
• Fifty years of chemical research at Farmitalia.

  2009cites this paper
• The role of aromasin in the hormonal therapy of breast cancer

  2009cites this paper
• Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.

  2009cites this paper
• Chapter 8 – The Process of Drug Discovery

  2009cites this paper
• Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

  2009cites this paper
• Antiproliferative effect of exemestane in lung cancer cells

  2009cites this paper
• Covalent modifiers: an orthogonal approach to drug design.

  2009cites this paper
• Synthesis and evaluation of novel 4-amino-4,6-androstadiene-3,17-dione: an analog of formestane.

  2008cites this paper
• Experience with exemestane in the treatment of early and advanced breast cancer.

  2008cites this paper
• Experience with Exemestane in the Treatment of Early and Advanced Breast Cancer

  2008cites this paper
• Aromatase inhibitors and models for breast cancer

  2008cites this paper
• The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.

  2008cites this paper
• Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase.

  2007cites this paper
• The discovery and mechanism of action of letrozole

  2007cites this paper
• Bioavailability File: Exemestane

  2007cites this paper
• Letrozole in the extended adjuvant setting: MA.17

  2007cites this paper
• Roles for estrogen in bone loss and arthralgia during aromatase inhibitor treatment

  2007cites this paper
• Novel targets for lung cancer therapy

  2006cites this paper
• Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor.

  2006influential citation
• Sex Hormones (Male): Analogs and Antagonists

  2006cites this paper
• Aromatase Inhibitors

  2006cites this paper
• Update on the use of aromatase inhibitors in breast cancer

  2006cites this paper
• Chemoprevention of breast cancer: current status and future prospects.

  2006cites this paper
• Chemoprevention of breast cancer 2250 occurrence of breast cancer is correlated with estrogens , chemicals produced by the ovaries

  2006cites this paper
• Aromatase inhibitors and bone health in women with breast cancer.

  2006cites this paper
• The Process of Drug Discovery

  2006cites this paper
• The ne w e ngl and j our na l of medicine

  2006cites this paper
• Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.

  2005cites this paper
• Interrelationships between aromatase and cyclooxygenase-2 and their role in the autocrine and paracrine mechanisms in breast cancer

  2005cites this paper
• The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study

  2005cites this paper
• Aromatase inhibitors in the treatment of breast cancer.

  2005cites this paper
• A review of exemestane in the management of breast cancer

  2005cites this paper
• Effect of exemestane on the lipidemic profile of post- menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy

  2005cites this paper
• Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy

  2005cites this paper
• A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors

  2004cites this paper
• Aromatase inhibitors — mechanisms of steroidal inhibitors

  2004cites this paper
• Effects of the Steroidal Aromatase Inhibitor Exemestane and the Nonsteroidal Aromatase Inhibitor Letrozole on Bone and Lipid Metabolism in Ovariectomized Rats

  2004cites this paper
• Role of aromatase inhibitors in the treatment of breast cancer.

  2004cites this paper
• Aromatase Inhibitors: New Endocrine Treatment of Breast Cancer

  2004cites this paper
• The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.

  2004cites this paper
• Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone

  2004cites this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cites this paper
• 新規非可逆的アロマターゼ阻害薬エキセメスタン（アロマシン®）の薬理学的特性および臨床効果

  2003cites this paper
• Update on the current use of hormonals as therapy in advanced breast cancer

  2003cites this paper
• [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor].

  2003cites this paper
• Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer.

  2003cites this paper
• Male Sex Hormones, Analogs, and Antagonists

  2003cites this paper
• Antiaromatase agents: evolving role in adjuvant therapy.

  2002cites this paper
• Overview of the Pharmacology of the Aromatase Inactivator Exemestane

  2002cites this paper
• Exemestane: treatment of breast cancer with selective inactivation of aromatase.

  2002cites this paper
• Aromatase Inhibitors and Inactivators for Breast Cancer Therapy

  2002cites this paper